Drug Profile
Research programme:cancer therapeutics - MacroArray Technologies
Alternative Names: DNA ZYM oligonucleotides; DNA-ZYM; PCADM-1 DNA ZYM-1P; PCADM-1 DNA ZYM-1P oligonucleotideLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator MacroArray Technologies
- Class Antineoplastics; Oligonucleotides
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Prostate cancer
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Prostate-cancer in USA (IV, Injection)
- 27 Oct 2016 Preclinical trials in Cancer in USA (IV)